|
⚲
|
| Keyboard |
| Great Point Partners LLC
✚
|
|
|---|---|
| CRD # | 158423 |
| SEC # | 801-73834 |
| CIK # | 0001281446 |
| AUM | 1,777.1 M (2026-03-31) |
| Employees | 28 (82% Investors, 14% Brokers) |
| Fees | |
| Minimum | |
| Phone | 203-971-3300 |
| Address | 165 Mason Street Greenwich, CT 06830 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
ITEM 5 – FEES AND COMPENSATION The Hedge Funds Great Point generally receives an annual management fee of 2% of the net assets of each Hedge Fund, generally payable in monthly installments in advance based on the Hedge Fund’s net assets on the first day of each month. The fee is deducted from the Hedge Funds’ assets. Great Point generally is entitled to a 20% performance allocation based on capital appreciation of the BMVF assets, including unrealized appreciation, after deduction of expenses and subject to exceeding the previous high-water mark. Great Point generally is entitled to a 20% performance fee based on capital appreciation of the BMOVF assets, including unrealized appreciation, after deduction of expenses and subject to exceeding the previous high-water mark. In addition to the management and performance allocations/fees, the Hedge Funds incur fees and expenses such as investment-related and other trading-related expenses (including, without limitation, all brokerage (including prime brokerage) commissions and fees, investment banking fees and expenses, expenses relating to short sales, clearing and settlement charges, custodial fees, bank service fees, interest on margin accounts and other indebtedness, borrowing charges, consulting and other professional fees relating to due diligence of particular investments or contemplated investments (in each case whether or not the applicable investment is consummated) and reasonable travel and related expenses incurred in connection with due diligence and other work performed on behalf of the Hedge Fund (including premium class air travel and expenses for reasonable lodging, meals and related items), all research-related expenses (including, without limitation, news and quotation equipment and services, and expenses related to obtaining, processing and analyzing “big data” or “alternative data”), data feeds, reports, subscriptions, licenses, investment-and trading-related computer hardware, information systems, and software, including trade order management software (i.e., software used to route trade orders), and fees and expenses of attending professional and industry conferences or obtaining third-party research, data, analytics, modeling, structuring, pricing and execution services that are related to the Hedge Fund’s investment activities (including any “expert network”), professional fees (including, without limitation, expenses of attorneys, consultants, statisticians and experts); administration expenses (including the fees and expenses of any administrator); annual meeting expense; accounting expenses (including portfolio accounting software); organizational and reorganizational expenses; operating expenses; including the following: fees and expenses relating to information technology hardware, software or other technology (including costs of software licensing, implementation, data management and recovery services and custom development) used to research investments, evaluate and manage risk, facilitate valuations, facilitate accounting functions, facilitate compliance with the rules of any self-regulatory organization or applicable law (including reporting obligations), facilitate and manage the order execution of securities or otherwise manage the Fund or any trading vehicle, such as Bloomberg terminals, portfolio management systems, risk management systems and order management systems; fees and expenses of third-party risk management products, models and services; third-party administrative fees and expenses; audit expenses; legal expenses; fees and expenses associated with the preparation or distribution of the Fund’s financial statements, tax returns, tax estimates and Schedules K-1 and, if applicable, K-3, any reporting to the limited partners or any other administrative, regulatory or other Hedge Fund -related reporting or filing (including Section 13 filings), any investor administrative tools such as investor portals and third-party reporting software; communications expenses, and any Fund-related filings or reports required by the Alternative Investment Fund Managers Directive of the European Union or any similar law, rule or regulation and expenses related to compliance with such; costs of printing and mailing reports and notices; corporate licensing; all fees, expenses, costs and liabilities incurred in connection with litigation, arbitration, mediation, claim, proceeding or other extraordinary events involving the Hedge Fund; governmental fees and regulatory expenses (including filing fees);charges, and all expenses incurred by Great Point in its capacity as the Hedge Fund’s tax matters partner, or a similar role under applicable state or local tax law; expenses incurred in connection with the offering and sale of the interests in the Hedge Fund and other similar expenses related to the Hedge Fund; premiums for liability insurance (including directors and officers and errors and omissions insurance) covering Great Point and its affiliates and their respective members, directors, officers, employees and agents and other indemnity expenses (including attorney’s fees incurred in connection therewith); the management fee and the incentive allocation; costs of preparing and distributing reports and notices; taxes; expenses incurred in connection with negotiating and complying with provisions of any side letter agreement; and extraordinary expenses and other similar expenses related to the Hedge Fund as Great Point determines in its sole discretion , including the following: indemnification expenses; fees and expenses incurred in connection with any tax audit by any taxing authority, including any related administrative settlement and judicial review; and fees and expenses incurred in connection with the reorganization, dissolution, winding up or termination of the Hedge Fund or any trading vehicle. Specific information regarding the management fees, performance allocations/fees and expenses for ... |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
ITEM 7 – TYPES OF CLIENTS Great Point provides advisory services to private funds that are considered hedge funds or private equity funds. The investors participating in the Funds generally include individuals, banks or thrift institutions, other investment entities, university endowments, sovereign wealth funds, family offices, pension or profit-sharing plans, trusts, estates, or charitable organizations or other corporations or business entities, and include, directly or indirectly, principals or other employees of Great Point and its affiliates and members of their families, as well as service providers or other relationships retained by Great Point including members of the Medical Advisory Board and the CEO Advisory Board. Great Point does not provide investment advice directly to investors in the Funds on an individual basis. Great Point also from time to time provides advisory services to Managed Accounts which in such a case will be institutional investors. The Hedge Funds and the Private Equity Funds generally require a minimum initial subscription from investors and require them to meet suitability requirements. For a Managed Account, Great Point generally requires a significant minimum investment. Great Point may waive minimum account sizes in its sole discretion. |
| CIK | Period |
|---|---|
| 0001281446 |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Apogee Therapeutics Inc | 31.5 | ||
| Vor Biopharma Inc | 31.2 | ||
| JATT Acquisition Corp | 25.1 | ||
| Amylyx Pharmaceuticals Inc | 24.3 | ||
| Nantkwest Inc | 23.0 | ||
| Nektar Therapeutics | 22.8 | ||
| Sol-Gel Technologies Ltd | 21.7 | ||
| Alumis Inc | 18.9 | ||
| Bright Minds Biosciences Inc | 16.1 | ||
| Annexon Inc | 13.8 | ||
| Health Sciences Acquisitions Corp | 13.6 | ||
| Aerovate Therapeutics Inc | 13.6 | ||
| Contineum Therapeutics Inc | 10.5 | ||
| Zenas Biopharma Inc | 10.2 | ||
| Aquinox Pharmaceuticals Inc | 10.1 | ||
| Helix Acquisition Corp | 9.3 | ||
| Eliem Therapeutics Inc | 9.1 | ||
| ARCA Biopharma Inc | 9.0 | ||
| Eupraxia Pharmaceuticals Inc | 8.7 | ||
| Vera Therapeutics Inc | 8.0 | ||
| Evommune Inc | 7.5 | ||
| LB Pharmaceuticals Inc | 7.4 | ||
| Olivia Ventures Inc | 7.1 | ||
| Scynexis Inc | 6.9 | ||
| Neuralstem Inc | 6.0 | ||
| Context Therapeutics Inc | 5.9 | ||
| Camp Nine Inc | 5.9 | ||
| Silence Therapeutics PLC | 5.4 | ||
| Unicycive Therapeutics Inc | 5.2 | ||
| Prev | Page 1 | Next | |||
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | GPP IV - Eutecma LLC | 2026-03-31 | 1.0 M | |
| PE | GPP IV - Lyocontract LLC | 2025-03-28 | 77.7 M | |
| PE | GPP IV - LUDI LLC | 2024-10-14 | 4.6 M | |
| PE | GPP - CF I LP | [2023-03-31] | 36.4 M | 25.6 M |
| Offered $36,415,770 · Filed 2022-12-12 (D) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | GPP III - Ephicacy LLC | 2023-03-31 | 21.9 M | |
| PE | GPP III - Ixcells LLC | 2023-03-31 | 1.8 M | |
| PE | Great Point Partners IV LP | [2022-05-05] | 432.0 M | 658.5 M |
| Offered $500,000,000 · Filed 2022-04-15 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining $68,030,000 · Duration One year or less · Commission $680,000 · Revenue Decline to Disclose | ||||
| PE | GPP III - PCM LLC | 2022-03-31 | 40.2 M | |
| PE | GPP II-A Salmon AIV LP | 2021-02-25 | 20.6 M | |
| PE | GPP III - MLM LLC | 2021-02-25 | 5.4 M | |
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 17 | 1.8 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 17 | 1.8 |
| By Discretionary | ||
| Discretionary | 17 | 1.8 |
| Non-Discretionary | 0 | 0.0 |
| Total | 17 | 1.8 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.2 | |
| United States Persons | 1.6 | |
| Total | 17 | 1.8 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Riyaz Nooruddin | Director | 61 | 22 | |
| Alan Kelly | Director | 39 | 17 | |
| Charl Grobler | Director | 7 | 5 | |
| Jeffrey Jay | Director, Executive Officer | 12 | 2 | |
| David Kroin | Executive Officer | 7 | 2 | |
| Great Point Partners LLC | Executive Officer, Promoter | 3 | 2 | |
| Great Point GP LLC | Executive Officer | 2 | 2 | |
| Great Point Partners CF I GP LLC | Promoter | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001281446] | |
| 13F-NT | [0001281446] | |
| 3 | [0001281446] | |
| 4 | [0001281446] | |
| SC 13D | [0001281446] | |
| SC 13G | [0001281446] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $0.9B |
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Adamas Pharmaceuticals Inc ADMS
Common Stock
|
2017-06-21 | Sell | 10,000 | $17.44 | 174,400 |
|
Adamas Pharmaceuticals Inc ADMS
Common Stock
|
2017-06-20 | Sell | 20,000 | $17.35 | 347,000 |
|
Adamas Pharmaceuticals Inc ADMS
Common Stock
|
2017-06-19 | Sell | 350,000 | $17.05 | 5,967,500 |
|
Connecture Inc CNXR
Common Stock
|
2015-06-30 | Gift | 10,000 | $0.00 | |
|
Connecture Inc CNXR
Common Stock
|
2015-06-10 | Other | 1,375,733 | $0.00 | |
|
Connecture Inc CNXR
Common Stock
|
2015-06-10 | Other | 39,703 | $0.00 | |
|
Connecture Inc CNXR
Common Stock
|
2015-06-10 | Other | 47,235 | $0.00 | |
|
Connecture Inc CNXR
Common Stock
|
2015-06-10 | Other | 36,493 | $0.00 | |
|
Connecture Inc CNXR
Common Stock
|
2015-06-10 | Other | 28,696 | $0.00 | |
|
Apyx Medical Corp BVX
Series B Convertible Preferred Stock · derivative
|
2015-03-17 | Grant | 3,588,139 | ||
|
Apyx Medical Corp BVX
Common Stock
|
2015-03-17 | Grant | 480,000 | $2.50 | 1,200,000 |
|
Apyx Medical Corp BVX
Common Stock Warrants (right to buy) · derivative
|
2015-03-17 | Disposed to issuer | 5,250,000 | ||
|
Apyx Medical Corp BVX
Series A Convertible Preferred Stock · derivative
|
2015-03-17 | Disposed to issuer | 3,500,000 | ||
|
Connecture Inc CNXR
Series B Preferred Stock · derivative
|
2014-12-17 | Conversion | 17,696,553 | $0.00 | |
|
Connecture Inc CNXR
Common Stock
|
2014-12-17 | Sell | 395,886 | $8.00 | 3,167,088 |
|
Connecture Inc CNXR
Common Stock
|
2014-12-17 | Conversion | 5,898,851 | ||
|
Apyx Medical Corp BVX
Stock Option (Option to Buy) · derivative
|
2014-07-17 | Grant | 12,000 | $0.00 | |
|
WaferGen Bio-systems Inc WGBS
Common Stock
|
2013-11-15 | Conversion | 899,893 | ||
|
WaferGen Bio-systems Inc WGBS
Common Stock
|
2013-11-15 | Conversion | 899,893 | ||
|
WaferGen Bio-systems Inc WGBS
Series 1 Convertible Preferred Stock · derivative
|
2013-11-15 | Conversion | 357.76 | ||
| showing 20 of 39 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
D2 Asset Management LP
✚
|
TX | 1,825.9 M |
|
ParaFi Capital LP
✚
|
NY | 1,817.8 M |
|
Tensile Capital Management LP
✚
|
CA | 1,796.0 M |
|
Morgan Creek Capital Management LLC
✚
|
NC | 1,790.2 M |
|
QVT Financial LP
✚
|
NY | 1,786.7 M |
|
Alta Park Capital LP
✚
|
CA | 1,779.6 M |
|
OFS Capital Management LLC
✚
|
IL | 1,760.0 M |
|
RCF Management LLC
✚
|
CO | 1,757.0 M |
|
Parkman Healthcare Partners LLC
✚
|
CT | 1,744.0 M |
|
Long Path Partners LP
✚
|
CT | 1,732.8 M |